Critical Pharmacodynamic Warning

alectinib affects the 3A457 metabolic pathway.

When patients take alectinib concurrently with drugs metabolized by 3A457, the risk of adverse effects may significantly increase. This interaction affects drug clearance and systemic exposure, potentially leading to toxicity or reduced therapeutic efficacy.

Clinical Impact: As a under review, alectinib can alter the metabolism of substrate drugs, requiring careful monitoring and potential dose adjustments.

Clinical Overview for alectinib

This page outlines known interaction pathways involving alectinib, focusing primarily on its profile as a under review affecting the 3A457 pathway.

Enzyme Interaction Profile

alectinib demonstrates under review potency against 3A457. Clinical significance of this interaction requires further evaluation.

Inhibitor

A substance that slows down or prevents an enzyme from metabolizing a drug. Inhibitors can lead to increased drug concentrations in the body, potentially causing toxicity or enhanced therapeutic effects.

Clinical Example: alectinib affects 3A457

Inducer

A substance that speeds up enzyme activity, causing drugs to be cleared from the body faster. Inducers can reduce drug effectiveness by lowering concentrations below therapeutic levels.

Known Inducers: enzalutamide
Interaction Details
Drug Name alectinib
Affected Enzyme 3A457
Inhibitor Strength under review Under Evaluation
Inducers enzalutamide
Inhibitors ciprofloxacin
Clinical Recommendations

Clinical significance pending review. Exercise caution.

Monitoring Parameters:
  • Therapeutic drug levels
  • Adverse effect monitoring
  • Clinical response assessment
Dose Considerations:
  • Consider dose reduction
  • Evaluate alternative therapies
  • Adjust based on response
Quick Facts
Interaction ID
2017
Primary Pathway
3A457
Interaction Type
Enzyme Inhibition
Clinical Phase
Under Evaluation
Clinical Significance

Clinical significance requires further evaluation.

Information Sources
  • FDA Drug Interaction Database
  • Clinical Pharmacology Guidelines
  • Pharmaceutical Labeling Information
  • Published Clinical Studies
Last updated: June 16, 2026
Back Return to Database